Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,105 questions in 84 reviews · Metabolic and Endocrine Disorders
current versionsNo studies 434 · 39.3%Ungraded 32 · 2.9%Very low 246 · 22.3%Low 237 · 21.4%Moderate 132 · 11.9%High 24 · 2.2%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Health‐related quality of life · participants with type 2 diabetes mellitus Sulphonylurea monotherapy for patients with type 2 diabetes mellitus (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · participants with type 2 diabetes mellitus Sulphonylurea monotherapy for patients with type 2 diabetes mellitus (2013) · Cochrane | RR 0.98 [0.61, 1.58] | 6 studies · 3528 participants | Low |
Intervention NR Cardiovascular mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs meglitinide [d. 12 months to 17 m... · participants with type 2 diabetes mellitus Sulphonylurea monotherapy for patients with type 2 diabetes mellitus (2013) · Cochrane | RR 1.47 [0.54, 4.01] | 6 studies · 3528 participants | Low |
Ipomoea batatas (Caiapo) tablets vs placebo Morbidity · people with type 2 diabetes mellitus Sweet potato for type 2 diabetes mellitus (2013) · Cochrane | no estimate extracted | NR | No studies |
Ipomoea batatas (Caiapo) tablets vs placebo Adverse effects · people with type 2 diabetes mellitus Sweet potato for type 2 diabetes mellitus (2013) · Cochrane | no estimate extracted | 3 studies · 140 participants | Very low |
Ipomoea batatas (Caiapo) tablets vs placebo Health‐related quality of life · people with type 2 diabetes mellitus Sweet potato for type 2 diabetes mellitus (2013) · Cochrane | no estimate extracted | NR | No studies |
Ipomoea batatas (Caiapo) tablets vs placebo Well‐being · people with type 2 diabetes mellitus Sweet potato for type 2 diabetes mellitus (2013) · Cochrane | no estimate extracted | NR | No studies |
Ipomoea batatas (Caiapo) tablets vs placebo Functional outcomes · people with type 2 diabetes mellitus Sweet potato for type 2 diabetes mellitus (2013) · Cochrane | no estimate extracted | NR | No studies |
Ipomoea batatas (Caiapo) tablets vs placebo Costs · people with type 2 diabetes mellitus Sweet potato for type 2 diabetes mellitus (2013) · Cochrane | no estimate extracted | NR | No studies |
Ipomoea batatas (Caiapo) tablets vs placebo HbA1c [%] (final values) · people with type 2 diabetes mellitus Sweet potato for type 2 diabetes mellitus (2013) · Cochrane | no estimate extracted | 2 studies · 122 participants | Very low |
Intervention NR Cardiovascular events · postmenopausal women with hypercholesterolaemia Isoflavones for hypercholesterolaemia in adults (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Death from any cause · postmenopausal women with hypercholesterolaemia Isoflavones for hypercholesterolaemia in adults (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · postmenopausal women with hypercholesterolaemia Isoflavones for hypercholesterolaemia in adults (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events [ · postmenopausal women with hypercholesterolaemia Isoflavones for hypercholesterolaemia in adults (2013) · Cochrane | no estimate extracted | 5 studies · 208 participants | Low |
Intervention NR Low‐density lipoprotein (LDL) cholesterol [ · postmenopausal women with hypercholesterolaemia Isoflavones for hypercholesterolaemia in adults (2013) · Cochrane | no estimate extracted | 3 studies · 132 participants | Very low |
Intervention NR Costs · postmenopausal women with hypercholesterolaemia Isoflavones for hypercholesterolaemia in adults (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Death from any cause · participants with hypertriglyceridaemia Chinese herbal medicines for hypertriglyceridaemia (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cardiovascular or cerebrovascular events · participants with hypertriglyceridaemia Chinese herbal medicines for hypertriglyceridaemia (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events [ · participants with hypertriglyceridaemia Chinese herbal medicines for hypertriglyceridaemia (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · participants with hypertriglyceridaemia Chinese herbal medicines for hypertriglyceridaemia (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Costs · participants with hypertriglyceridaemia Chinese herbal medicines for hypertriglyceridaemia (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serum triglyceride concentrations (mmol/L) [ · participants with hypertriglyceridaemia Chinese herbal medicines for hypertriglyceridaemia (2013) · Cochrane | no estimate extracted | 1 study · 60 participants | Very low |
Intervention NR Health‐related quality of life · overweight or obese adults Chromium picolinate supplementation for overweight or obese adults (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · overweight or obese adults Chromium picolinate supplementation for overweight or obese adults (2013) · Cochrane | no estimate extracted | 3 studies · 189 participants | Low |
Intervention NR Death from any cause · overweight or obese adults Chromium picolinate supplementation for overweight or obese adults (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · overweight or obese adults Chromium picolinate supplementation for overweight or obese adults (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Weight loss [kg] · overweight or obese adults Chromium picolinate supplementation for overweight or obese adults (2013) · Cochrane | no estimate extracted | 6 studies · 392 participants | Low |
Intervention NR Socioeconomic effects · overweight or obese adults Chromium picolinate supplementation for overweight or obese adults (2013) · Cochrane | no estimate extracted | NR | No studies |
Selenium (+LT4) vs placebo (+LT4) Change from baseline in health‐related quality of life · participants with Hashimoto's thyroiditis. Selenium supplementation for Hashimoto's thyroiditis (2013) · Cochrane | no estimate extracted | NR | No studies |
Selenium (+LT4) vs placebo (+LT4) Change from baseline in assessment of symptoms such as mood, fatigue and muscle weakness Short‐Form Health Survey · participants with Hashimoto's thyroiditis. Selenium supplementation for Hashimoto's thyroiditis (2013) · Cochrane | RR 4.67 [1.61, 13.5] | 1 study · 36 participants | Low |
Selenium (+LT4) vs placebo (+LT4) Proportion of participants reporting an adverse event · participants with Hashimoto's thyroiditis. Selenium supplementation for Hashimoto's thyroiditis (2013) · Cochrane | RR 2.71 [0.29, 25.66] | 3 studies · 258 participants | Low |
Selenium (+LT4) vs placebo (+LT4) Change from baseline in serum levels of anti‐thyroid peroxidase antibodies Decrease from 1508 to 25 IU/L · participants with Hashimoto's thyroiditis. Selenium supplementation for Hashimoto's thyroiditis (2013) · Cochrane | no estimate extracted | 4 studies · 252 participants | Low |
Selenium (+LT4) vs placebo (+LT4) Change from baseline in LT4 replacement dosage at end of study · participants with Hashimoto's thyroiditis. Selenium supplementation for Hashimoto's thyroiditis (2013) · Cochrane | no estimate extracted | NR | No studies |
Selenium (+LT4) vs placebo (+LT4) Economic costs · participants with Hashimoto's thyroiditis. Selenium supplementation for Hashimoto's thyroiditis (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · Patients with type 2 diabetes mellitus Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · Patients with type 2 diabetes mellitus Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin (2012) · Cochrane | no estimate extracted | 3 studies · 523 participants | Moderate |
Intervention NR Well‐being · Patients with type 2 diabetes mellitus Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin (2012) · Cochrane | no estimate extracted | 4 studies · 928 participants | Moderate |
Intervention NR Patient satisfaction · Patients with type 2 diabetes mellitus Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin (2012) · Cochrane | no estimate extracted | 4 studies · 928 participants | Moderate |
Intervention NR Hypoglycaemic episodes · Patients with type 2 diabetes mellitus Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin (2012) · Cochrane | no estimate extracted | 6 studies · 2492 participants | Moderate |
Intervention NR Costs · Patients with type 2 diabetes mellitus Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin (2012) · Cochrane | no estimate extracted | 2 studies · 514 participants | Moderate |
Intervention NR HbA1c [%] · Patients with type 2 diabetes mellitus Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin (2012) · Cochrane | no estimate extracted | 9 studies · 2324 participants | Moderate |
Intervention NR All‐cause mortality (ticlopidine vs placebo) · patients with type 2 diabetes mellitus Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2… (2012) · Cochrane | RR 1.29 [0.71, 2.32] | 1 study · 335 participants | Moderate |
Intervention NR Vascular mortality (ticlopidine vs placebo) · patients with type 2 diabetes mellitus Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2… (2012) · Cochrane | RR 0.94 [0.47, 1.88] | 1 study · 335 participants | Moderate |
Intervention NR Myocardial infarction (fatal and non‐fatal) (ticlopidine vs placebo) · patients with type 2 diabetes mellitus Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2… (2012) · Cochrane | RR 0.78 [0.39, 1.57] | 1 study · 335 participants | Moderate |
Intervention NR Stroke (fatal and non‐fatal) (a. ticlopidine vs aspirin) (b. clopidogrel vs aspirin & dipyramidole) · patients with type 2 diabetes mellitus Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2… (2012) · Cochrane | RR 0.56 [0.37, 0.94] | 1 study · 597 participants | Moderate |
Intervention NR Health‐related quality of life · patients with type 2 diabetes mellitus Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2… (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse effects · patients with type 2 diabetes mellitus Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2… (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Costs · patients with type 2 diabetes mellitus Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2… (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Death from any cause ( · patients with diabetes mellitus Cinnamon for diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity ( · patients with diabetes mellitus Cinnamon for diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |